Skip to content


Play Video

“Modest valuation, upcoming re-rating catalysts, and large untapped opportunity makes Shackelford a key name to monitor.”

- Intro-Act Inc. Vol 177 January 18, 2023.

To contact investor relations, please email us at

Invest in Shackelford

Shackelford Pharma’s Regulation A Financing is now open. Investors are required to fill out the form below to begin the investment process.

Please check your JUNK/SPAM email folder if your invitation email from Dealmaker/Shackelford does not arrive in your inbox.

Invest Shackelford